Search Results - Metabolic+disorders

4 Results

Sort By:

Topical treatment with TGFbeta3 to facilitate skin and corneal wound healing in diabetic patients

Background: Diabetes affects approximately 170 million people worldwide, including 20.8 million in the USA, and by 2030 these numbers are projected to double. Diabetics often experience slow or limited wound healing. Slow wound healing allows longer time for the development of infections and can contribute to the formation of bed sores and ulcers....

Published: 9/16/2019 | Inventor(s): Fu-Shin Yu

Keywords(s): Diabetes

Category(s): Medical, Biologicals, Biomedical, Drug Discovery, Metabolic disorders, Protein/peptides, Therapeutics, Life Science

Dual action nanocarrier combining CXCR4 antagonist and polyplex gene delivery for treatment of metastatic cancer and other diseases

Novel bio-reducible polymer compositions which combine the ability to act as a CXCR4 antagonist and simultaneously provide enhanced gene delivery through the formation of inert nanocarrier polyplexes have been developed. As would be expected for biodegradable polymers, the cytotoxicity of these nanocarrier compositions are very low with measured IC50...

Published: 11/11/2021 | Inventor(s): David Oupicky, Jing Li

Keywords(s): Cancer, Cancer Therapies, Compound, Drug Delivery, Drug Target, Formulation, Imaging, Nanomaterials, Pharmaceuticals, Therapeutics

Category(s): Drug Delivery, Gene Therapy, Therapeutics, Life Science, Oncology, Nano-based, Metabolic disorders, Biologicals

Novel Mammalian Putative Phosphatidylinositol-4-Phosphate-5-Kinase

This invention is a novel mammalian gene involved in membrane trafficking, more specifically, insulin‑induced translocation of the fat/muscle-specific glucose transporter GLUT4. Background & Unmet Need: Both Type I (Juvenile onset) and Type II (Maturity onset) Diabetes Mellitus result in a profound state of high glucose in the circulation....

Published: 2/14/2022 | Inventor(s): Assia Shisheva

Keywords(s): DNA, Drug Target, Therapeutics

Category(s): Diseases, Life Science, Metabolic disorders, Therapeutics, Biologicals

DNA Molecule Encoding the B3 Adrenegic Receptor

This technology describes the correct protein sequence of the β3 receptor to aid in the development of adult-onset diabetes drugs. Background & Unmet Need: The β3 receptor is currently being developed as a therapeutic target for human obesity and adult onset diabetes mellitus by several pharmaceutical companies. In order to develop...

Published: 3/2/2022 | Inventor(s): James Granneman, Kristine Lahners, Donald Rao

Keywords(s): Diabetes, Disease, DNA, Drug Target, Obesity, Therapeutics

Category(s): Life Science, Metabolic disorders, Diagnostics, Research tools, Receptors/targets